BioCentury
ARTICLE | Clinical News

Serelaxin: Development discontinued

April 28, 2017 8:06 PM UTC

Novartis said it discontinued development of serelaxin. In March, serelaxin missed the co-primary endpoints in the Phase III RELAX-AHF-2 trial to treat AHF (see BioCentury, March 24)...

BCIQ Target Profiles

Relaxin 2 (RLN2) (H2)